Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03967990
Other study ID # STUDY00007518
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 20, 2018
Est. completion date October 30, 2023

Study information

Verified date February 2024
Source Arizona State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effects of 3 different corn flours: (1) whole grain corn flour, (2) 50% refined corn flour + 50% corn bran derived from whole corn meal, and (3) refined corn flour, on cardio-metabolic outcomes and changes in the gut microbiome.


Description:

Dietary fibers are extremely complex and foster health in a variety of ways that are not fully understood. The Adequate Intake of fiber (14 g per 1000 kcal consumed) is based on data that strongly support a relationship with cardiovascular disease prevention (Slavin, 2013). While cereal fibers have been shown to be most effective at reducing cardiovascular disease risk (IOM, 2002), the components of dietary fiber (e.g. germ, bran) that exert this effect remain inadequately studied in cardiometabolic outcomes. Further, specific types of dietary fiber (natural and synthetic) have been shown to increase beneficial microbial species in the gastrointestinal tract, which are accompanied by improvements in inflammatory and metabolic disease markers. Very little is known about how isolated or intact fiber in whole grains solicit beneficial health effects via microbial mechanisms. Our goal is to study both changes in cardiometabolic outcomes and the gut microbiome after consuming different types of corn-based meals. Aim 1: To evaluate cardio-metabolic outcomes (primary outcome: LDL cholesterol) after consuming 48 g/d of whole grain corn flour, 50% refined corn flour + 50% corn bran derived from whole corn meal, and refined corn flour for 4 weeks in adult males and females with elevated LDL cholesterol in a crossover design. Aim 2: To evaluate changes in the gut microbiome after consuming 48 g/d of whole grain corn flour, 50% refined corn flour + 50% corn bran derived from whole corn meal, and refined corn flour for 4 weeks in adult males and females with elevated LDL cholesterol in a crossover design.


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date October 30, 2023
Est. primary completion date August 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Healthy English and Spanish speaking males and females with elevated circulating cholesterol levels (LDL-c = 120 mg/dL). - Individuals with LDL-c > 190 mg/dL will be permitted to participate but must provide a letter from their doctor stating that they are comfortable with their participation in the study. Exclusion Criteria: - recent weight fluctuations (> 5 lb in past 3 months), following specialized or restrictive diets (e.g. carbohydrate restriction, veganism) - use of supplements (antioxidants, fiber, botanicals) - allergies to dairy, egg, wheat, corn or gluten - use of antibiotics in the past 2-3 months - use of lipid lowering medications - regular physical activity = 30 min/d for = 5 days/wk - history of thyroid disorders, diabetes, heart disease, cancer, hepatitis, inflammatory conditions and/or gastrointestinal disorders which may impact gut function and metabolism - anyone with a fear of needles or blood draws - If female, women may not be pregnant or lactating during the study. - Unwillingness to comply with study protocols will also result in exclusion from the study. - Participants in this study will not be eligible if they are participating in other research studies at the same time.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Refined cornmeal flour
48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
50/50 refined cornmeal-bran mix
48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
Whole grain cornmeal flour
48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Locations

Country Name City State
United States Arizona Biomedical Collaborative Phoenix Arizona

Sponsors (2)

Lead Sponsor Collaborator
Arizona State University North American Millers Association - Corn Division

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary LDL Cholesterol Serum LDL cholesterol concentrations will be measured at the 0 and 4 weeks for each cornmeal intervention 0 weeks, 4 weeks
Primary HDL Cholesterol Serum HDL cholesterol concentrations will be measured at the 0 and 4 weeks for each cornmeal intervention 0 weeks, 4 weeks
Secondary Gut Microbiome Diversity Fecal gut microbiome communities will be sequenced using microbial DNA extracted from samples at 0 and 4 weeks for each cornmeal intervention. Amplified copies of the 16S rRNA gene will be evaluated for treatment differences in alpha (within-sample richness and evenness) and beta diversity (between-sample community structure). Relative and differential abundance of individual microbial taxa will also be measured. 0 weeks, 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05793112 - INF108F in Infants With Food Protein Induced Proctocolitis Phase 4
Active, not recruiting NCT04327141 - Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women N/A
Recruiting NCT04117321 - Mother-infant Microbiota Transmission and Its Link to the Health of the Baby
Recruiting NCT05655910 - Enhanced Nutritional Optimization in LVAD Trial N/A
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Active, not recruiting NCT05931471 - Yogurt and GI Health N/A
Recruiting NCT03797417 - Gut Microbiome and Metabolic Pathways Changes in Vitiligo
Withdrawn NCT06006416 - Effect of Fenugreek Fibre on Gut Microbiome Phase 3
Recruiting NCT06206486 - The Gut Microbiome and Serum Metabolites as a Biological Mechanism Underlying Pain in Kidney Transplantation
Completed NCT02655250 - Neonatal Microbiome Validity Study
Recruiting NCT05670288 - Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury
Not yet recruiting NCT03975764 - Fecal Microbiota in Preterm Birth
Completed NCT03219931 - NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants Phase 4
Recruiting NCT04447365 - The Correlation Between Gut Microbiome-host Interaction and Ventricular Arrhythmias.
Recruiting NCT04466072 - Gut Microbiome and Ventricular Arrhythmias
Not yet recruiting NCT06130137 - Gut Microbiome in People Living With HIV and HBV
Recruiting NCT06260579 - Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity N/A
Completed NCT04511052 - Probiotics for Enhanced Tissue Carotenoid Status in Premenopausal Women Phase 1/Phase 2
Active, not recruiting NCT06424691 - Infant Restore: Efficacy of Microbiome Analysis and Education N/A
Recruiting NCT06404749 - Fungal Fiber for Gut Health N/A